NCT07123545View on ClinicalTrials.gov

Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2029

Conditions
Advanced Hepatocellular Carcinoma (HCC)
Interventions
BIOLOGICAL

iNeo-Vac-P01 Personalized Neoantigen Peptide Vaccine

Administered subcutaneously at 0.3 mg/peptide on Days 1, 4, 8, 15, 22, 52, and 82, followed by booster immunizations every 2-3 months.

BIOLOGICAL

iNeo-Vac-T01 Personalized T Cell Injection

Administered via intravenous infusion: Dose Level 1: 5×10⁹ to 10×10⁹ cells; Dose Level 2: 1×10¹⁰ to 5×10¹⁰ cells.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

Hangzhou Neoantigen Therapeutics Co., Ltd.

INDUSTRY

lead

Zhejiang University

OTHER